Profluent just closed a $106M Series C, and the energy around this one feels like someone finally handed biology the upgrade it has been begging for. Altimeter Capital and Bezos Expeditions co-led the round, with Spark Capital, Insight Partners, and Air Street Capital doubling down again. That kind of investor stack does not chase noise. It chases inevitability. Ali Madani and Alexander Meeske built Profluent on a simple but relentless idea: if life runs on code, then it is time we start designing instead of scavenging. Protein engineering has spent decades hunting through nature like it lost its keys. Profluent walked in with frontier AI and a 115B+ protein atlas and said there is a better way.
Once you see ProGen3, you understand the confidence. Models up to 46B parameters, trained on 1.5T amino acid tokens pulled from 3.4B full length proteins. Scaling laws not as theory but as working reality. Better models generating better proteins. Antibodies created in a single shot across 20 therapeutic targets. Gene editors slimmed to 592 residues so they fit inside a single AAV like they were born for it. This is not iteration. It is intention. And the field felt that shift the moment OpenCRISPR-1 hit. Four million novel CRISPR, Cas proteins, a 4.8x jump in diversity across Cas9, Cas12a, and Cas13 families, and >80% of them showing high confidence structural folds. Then the Nature paper confirmed what thousands of GitHub and AddGene downloads had already made obvious. The world’s first AI created genome editor edits human cells with fewer off target events and lower immunogenicity than natural SpCas9. Evolution is patient. Profluent is not.
The partnerships only sharpen the picture. Corteva Agrisciences tapped Profluent to power its Genlytix ecosystem for sustainable crop innovation. Revvity teamed up for AI enhanced adenine deaminase base editors. The Rett Syndrome Research Trust put $1M behind a collaboration for therapeutic gene editing. IDT stepped in as a commercial conduit. When every corner of biotechnology starts orbiting the same company, it usually means someone has built the missing layer the industry has been waiting on.
The leadership roster reads like a cheat code. Ali Madani carrying the ProGen moonshot from Salesforce Research into a platform built to scale. Alexander Meeske with 18 years of CRISPR work woven through Harvard, Rockefeller, and UW. Hilary Eaton steering business development with experience from Editas Medicine, Vor Biopharma, and Tome Biosciences. Peter Cameron translating CRISPR systems into deployable platforms after a decade at Caribou and Spotlight Therapeutics. Investors saw the signal early. Spark Capital put Fraser Kelton and Nabeel Hyatt on the board during the previous round. Now Altimeter and Bezos Expeditions push the company into its next orbit.
This $106M round is fuel for expansion across therapeutics, diagnostics, agriculture, and biomanufacturing, and the path toward the first AI designed therapeutic reaching a human patient. Profluent is not just fluent in proteins anymore. It is teaching the world how to speak the language.
Startups Startup Funding Venture Capital Series C AI Biotech Biology Gene Editing Healthcare Health Tech Technology Innovation Tech Ecosystem Startup Ecosystem
